

Russian COVID vaccine eyeing Italian market roll out

Associazione Conoscere Eurasia, Italian partner of the Roscongress Foundation, together with the Embassy of the Republic of Italy in Russian Federation intend to assist Sputnik V get certified in Italy. Sputnik V, Russian adenoviral vector vaccine has been designed by the National Research Center for Epidemiology and Microbiology named after Honorary Academician Gamaleya of the Ministry of Health of the Russian Federation.

Antonio Fallico, President of the Associazione Conoscere Eurasia and Chairman of the Board of Directors, Banca Intesa, shared with Telenuovo that in November, together with the members of his family, he received the Russian vaccine and none of them reported any considerable side effects. According to Professor Fallico, it is in Europe's best interest to receive Russian vaccine for mass roll out on the continent.

“Sputnik V has been registered in Russia in August 2020. Prior to registration, it has been tested on roughly 700,000 people. Testing went well: the vaccine demonstrated high efficiency and lack of pathologically grave side effects. Mass vaccination campaign in Russia launched on 5 December. Italian scientists also confirm reliability of Sputnik V,” said Mr. Fallico.

Currently, the number of required doses and financial support is being discussed with the Italian Ministry of Health. Associazione intends to actively promote Sputnik V on other European markets.

Sputnik V was the first registered vaccine against SARS-CoV-2 in the world. The vaccine is produced using a unique approach involving the use of two different types of vectors based on human adenovirus, which makes it possible to enhance the immune response and form long-term immunity. The efficacy of the Russian vaccine is over 90 per cent. This approach has already been adopted by global pharmaceutical manufacturers. Namely, AstraZeneca will begin a clinical trial of its vaccine in combination with the adenovirus vector of the Sputnik V to improve the effectiveness of its own vaccine through the combined approach.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia's economic potential, promoting its national interests, and strengthening the country's image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation's events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress' various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 133 economic partners; industrialists' and entrepreneurs' unions; and financial, trade, and business associations from 70 countries worldwide.

roscongress.org